宫颈癌治疗前后检测血清sFas、sFasL的临床研究

目的探讨sFas、sFasL在宫颈癌发生、发展中的作用以及治疗前后检测的临床价值。方法采用酶联免疫法检测30例宫颈癌患者手术或化疗前后血清sFas、sFasL浓度，同时检测20例健康志愿者血清sFas、sFasL浓度。结果宫颈癌患者血清sFas、sFasL浓度[（8．60±0．27）、（2．96±O．65）μg/L]明显高于健康志愿者[（6．27±0．2S）、（O．21±0．05）μg/L]，差异有统计学意义（P〈O．05）。I、IIa期宫颈癌患者手术后2周sFas、sFasL浓度明显下降，IIb期及以后分期宫颈癌患者化疗后3周sFas、sFasL浓度明显增高，与治疗前比较差异有统计学意义（P〈0．05）。结论sFas、sFasL在宫颈癌的发生、发展和转移中起重要作用，监测血清中二者的变化有助于观察病情的变化。

Determination of serum sFas and sFasL in the clinical research before and after treatment of uterine cervix cancer

Objective To investigate the role of sFas and sFasL in the development and progression of uterine cervix cancer （UCC） and the clinical significance of detecting them. Method Serum sFas and sFasL levels of 30 UCC patients were detected by enzyme-hnked immunosobent assay （ELISA） before and after treatment （operation or chemotherapy）, at the same time serum sFas and sFasL levels of 20 healthy volunteers were also detected by ELISA. Results Serum sFas and sFasL levels of UCC patients [ （8.60 ± 0.27 ）, （2.96 ± 0.65 ）μg/L ] were obviously higher than those of healthy volunteers [ （6.27 ± 0.25 ）, （0.21 ± 0.05）μg/L], there was statistical significance （P 〈 0.05）. Serum sFas and sFasL levels of those who had operations decreased obviously 2 weeks after the operation, serum sFas and sFasL levels of those who had chemotherapy 3 weeks later increased, there was statistical significance when compared before and after treatment （P 〈 0.05）. Conclusions sFas and sFasL may play important roles in the development and progression of UCC, detection of serum sFas and sFasL levels may conduce to observe the changes of pathogenetic condition.